An experimental drug could be game-changing for millions of Americans with a higher genetic risk of cardiovascular disease.

The Phase II study found that lepodisiran significantly reduced levels of genetically inherited cardiovascular risk factor.

High Lipoprotein (a) is a genetic condition that increases the risk of early heart attacks and strokes. It is one of the most common genetic risk factors for cardiovascular disease, yet it remains ...

Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) ...

Heart disease remains the leading cause of death in America, and while many are aware of the impact of lifestyle choices on ...

Novel small interfering RNA (siRNA) agent lepodisiran drastically cut levels of lipoprotein(a), or Lp(a), in the phase II ALPACA trial. The 400-mg dose cut Lp(a) by 93.9 percentage points compared ...

I have had cholesterol tests for the past 30 years with HDL readings that had a low of 68 mg/dL and a high of 117 mg/dL.

Awareness Day, and it’s a great opportunity to discuss lipids and howlipoprotein (a) might differ from your general understanding of how cholesterol works in our bodies.

When you have high cholesterol levels, it can lead to several health issues which include heart attack, stroke, heart failure ...

Although cholesterol and TG serve several important functions within the body, they are insoluble particles and must be packaged into lipoproteins in order to circulate in the plasma, from sites ...

Eli Lilly and Company (NYSE: LLY) today announced positive Phase 2 results for lepodisiran, an investigational small interfering RNA (siRNA) therapy designed to lower the production of lipoprotein(a) ...